Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.

Ascentage Pharma, a China-based oncology drug developer based on research at University of Michigan, has filed for an initial public offering in Hong Kong having raised $150m last month. Founded in 2009, Ascentage is developing small-molecule drug treatments for cancer, hepatitis B virus and age-related diseases, and is currently overseeing 20 clinical trials for a…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.